Press Releases
Resolvyx to Present Data on Novel Resolvin Drug Candidates for Eye Disease at ARVO Annual Meeting
BEDFORD, MA — April 24, 2009 -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that new preclinical data on its resolvin drug candidates will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 3-7, 2009.
Resolvins have a unique mechanism with the potential to treat both ocular surface and retinal diseases. Resolvyx will make presentations at five sessions at this year’s ARVO annual meeting, continuing the interest in resolvin data from the eight presentations at last year’s 2008 ARVO meeting.
The schedule and meeting place for the sessions, together with the abstract information, are listed below:
Date & Time: Sunday, May 3, 2009, 2:45 - 4:30 PM
Session Title: Immunomodulation, Immunoregulation and Immunotherapies
Session Number: 144
Abstract: #819/A405
Title: RX-10001 (RvE1) an Endogenously Formed Immune Modulator Atenuates Clinical Signs of Autoimmune Disease in Rat CIA Model Concurrent with Inhibition of T-Cell Dependent Cytokines in Mixed Cell Populations from Draining Lymph Nodes
Location: Exhibit Hall A
Date & Time: Tuesday, May 5, 2009, 8:30 - 10:15 AM
Session Title: Angiogenesis
Session Number: 329
Abstract: #2965/A419
Title: Topical Administration of RX-10045 Reduces Laser-induced Choroidal Neovascularization
Location: Exhibit Hall A
Date & Time: Tuesday, May 5, 2009, 8:30 - 10:15 AM
Session Title: Angiogenesis
Session Number: 329
Abstract: #2967/A421
Title: An Analog of Resolvin E1 Inhibits Endothelial Cell Growth in Retina Following Laser-induced Choroidal Neovascularization
Location: Exhibit Hall A
Date & Time: Tuesday, May 5, 2009, 1:45 - 3:30 PM
Session Title: Stem Cells / Neuroprotection
Session Number: 358
Abstract: #3231/D657
Title: Laser-Induced Choroidal Neovascularization Is Reduced by Neuroprotectin D1
Location: Exhibit Hall D
Date & Time: Tuesday, May 5, 2009, 4:00 PM - 4:15 PM
Session Title: Cell Signaling and Corneal Wound Healing
Session Number: 372
Abstract: #3492
Title: Cell Signaling Pathways Underlying Resolvin Induced Increases in Human Corneal Epithelial Cell Migration: Effects Of RX-10001 (RvE1) and RX-10008
Location: Floridian Ballroom A
About Resolvins
Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an immuno-inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the insult has passed. Resolvins are shown to be highly potent and efficacious in pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others.
Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (like Crohn’s disease, psoriasis and rheumatoid arthritis), allergic diseases (like asthma) and chronic inflammatory diseases (like atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer’s disease). Resolvins offer an entirely novel biological approach to treating significant inflammatory diseases, with a decreased potential for immuno-suppression.
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of more than 55 patents and applications.
The company's headquarters are in Bedford, Massachusetts. For additional information, please visit http://www.resolvyx.com.